AstraZeneca (LON:AZN) has announced that the European Commission (EC) has approved Qtrilmet modified-release tablets to improve glycaemic control in adults with type-2 diabetes.
The approval is based on data from five Phase III trials which evaluated combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a background of metformin in patients with inadequately controlled T2D. The primary endpoint in these trials was mean change from baseline in HbA1c (average blood glucose levels) at week 24 or 52.
Across the trials, the combination of Forxiga, Onglyza and metformin was superior at reducing HbA1c compared to Forxiga with metformin, Onglyza with metformin, or glimepiride (an approved T2D sulphonylurea (SU) medicine) with metformin. The combination of Forxiga, Onglyza and metformin with or without glimepiride showed non-inferiority in reducing HbA1c versus the combined use of insulin and metformin with or without glimepiride. The safety results of the individual medicines in these trials were consistent with their known profile.
The EC has approved Qtrilmet to improve glycaemic control in adults with T2D when metformin with or without SU and either Onglyza or Forxiga does not provide adequate glycaemic control, or when T2D patients are already being treated with metformin, Onglyza and Forxiga.
Qtrilmet was approved in the US in May 2019 under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with T2D.
Qtrilmet is a once-daily oral medicine comprised of the selective sodium‑glucose co-transporter 2 (SGLT2) inhibitor Forxiga, the dipeptidyl peptidase‑4 (DPP‑4) inhibitor Onglyza and metformin hydrochloride extended release indicated as treatment in adults with T2D.
About AstraZeneca in CVRM
Cardiovascular, Renal & Metabolism (CVRM) together forms one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling comorbidities. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.